ZIM Laboratories Receives First Marketing Authorization in Australia for Rizatriptan Benzoate Orally Disintegrating Films via ZIMTAS

ZIM Laboratories Limited, a research-driven Pharmaceutical company, has announced that the Therapeutic Goods Administration (TGA), Australia has granted Marketing Authorization (MA) for its Central Nervous System (CNS) product ‘Rizatriptan Benzoate Orally Disintegrating Films’ through its Australian Subsidiary, ZIMTAS. This approval marks ZIM’s first Marketing Authorization in Australia and represents an important milestone in the Company’s strategy to expand its presence in regulated markets through innovative drug delivery technologies. The orally disintegrating film (ODF) formulation offers a patient-friendly alternative that enables rapid onset of action without the need for water, making it especially convenient for patients experiencing nausea or vomiting during migraine episodes. This authorization is expected to facilitate commercial launch in the Australian market via ZIMTAS, serve as a springboard for additional regulatory filings across the Asia-Pacific region, and further validate ZIM’s oral thin film platform as a globally relevant drug delivery technology.